J&J submits Risperdal follow-on
Johnson & Johnson submits NDA for paliperidone extended-release Nov. 29, giving the schizophrenia therapy a user fee date in late September 2006. The timeline puts J&J on track to launch paliperidone ER in advance of generic competition to Risperdal (risperidone), which could lose exclusivity as early as mid-2008. The agent is a metabolite of risperidone and uses J&J's proprietary OROS controlled-release technology, gained through the company's acquisition of Alza in 1999 (1"The Pink Sheet" April 19, 2004, p. 12)...
You may also be interested in...
Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies
The US FDA wants to expand the availability of surgical apparel – including gowns, hoods and examination gloves – for health care professionals to use for the duration of the COVID-19 public health crisis. That means the agency will “not object” to the use of gowns and gloves providing low-to-minimal protection, as long as they do not create an undue risk to patients or users.
Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.